Evidence map›Paper›PMID 40115836›Full record

ReviewJournal of clinical medicine research2025

Clinical Experience With Remimazolam in Neuroanesthesiology and Neurocritical Care: An Educational Focused Review.

Evan McPhaden, Joseph D Tobias, Ashley Smith

Abstract readReview
In one paragraph

Review in Journal of clinical medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Evan McPhadenOhio University Heritage College of Osteopathic Medicine - Dublin, Dublin, OH, USA.
Joseph D TobiasDepartment of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Ashley SmithDepartment of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remimazolam is an ultrashort-acting benzodiazepine, approved for clinical use by the United States Food & Drug Administration in 2020. Similar to other benzodiazepines, its clinical effects of sedation, anxiolysis, and amnesia are mediated through the gamma-aminobutyric acid A (GABA

Indexed as

Awake craniotomyBenzodiazepineNeuroanesthesiologyNeurosurgeryProcedural sedationRemimazolam

Identifiers

PMID40115836
PMCPMC11922631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.